[
  {
    "ts": null,
    "headline": "BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=11efc80e8755f0d0b3198e9934e056d8cab38e2a304273fc923b8ea8b2fd9bea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761920146,
      "headline": "BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands",
      "id": 137279641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=11efc80e8755f0d0b3198e9934e056d8cab38e2a304273fc923b8ea8b2fd9bea"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative",
    "summary": "Biogen (BIIB) delivered a notable turnaround this year, posting EPS growth of 32.1% after five years of average annual declines of 20.5%. Net profit margins improved to 15.3% from last year’s 12%. Forecasts now call for earnings to grow at 7.3% per year, even as revenue is expected to decline at a 0.8% annual rate over the next three years. With shares trading at $149.61, well below the estimated fair value of $333.62 and a price-to-earnings ratio of 14.3x compared to the industry average of...",
    "url": "https://finnhub.io/api/news?id=1352ca5e772e8fe9852adbbd50d9b10c53f9f378d324394efddc0ca3169f20b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761909397,
      "headline": "Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative",
      "id": 137279642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) delivered a notable turnaround this year, posting EPS growth of 32.1% after five years of average annual declines of 20.5%. Net profit margins improved to 15.3% from last year’s 12%. Forecasts now call for earnings to grow at 7.3% per year, even as revenue is expected to decline at a 0.8% annual rate over the next three years. With shares trading at $149.61, well below the estimated fair value of $333.62 and a price-to-earnings ratio of 14.3x compared to the industry average of...",
      "url": "https://finnhub.io/api/news?id=1352ca5e772e8fe9852adbbd50d9b10c53f9f378d324394efddc0ca3169f20b7"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Valuation: Exploring the Discount as Investor Sentiment Shifts",
    "summary": "Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest analysis for Biogen. While Biogen’s share price has dipped nearly 3% over the past month, the bigger picture shows momentum has faded, with a 90-day share price return of over 13% but a disappointing 1-year total shareholder return of -14%. That mix of short-term growth and long-term declines...",
    "url": "https://finnhub.io/api/news?id=7b20eb757762093c65ca51fa9a8f3644bf7dd51bb4bb69828975ac119385a332",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761884756,
      "headline": "Biogen (BIIB) Valuation: Exploring the Discount as Investor Sentiment Shifts",
      "id": 137275435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest analysis for Biogen. While Biogen’s share price has dipped nearly 3% over the past month, the bigger picture shows momentum has faded, with a 90-day share price return of over 13% but a disappointing 1-year total shareholder return of -14%. That mix of short-term growth and long-term declines...",
      "url": "https://finnhub.io/api/news?id=7b20eb757762093c65ca51fa9a8f3644bf7dd51bb4bb69828975ac119385a332"
    }
  }
]